Ahmad MA, Kareem O, Khushtar M, Akbar M, Haque MR, Iqubal A, Haider MF, Pottoo FH, Abdulla FS, Al-Haidar MB, Alhajri N (2022) Neuroinflammation: a potential risk for dementia. Int J Mol Sci. https://doi.org/10.3390/ijms23020616

PubMed  PubMed Central  Google Scholar 

Alvarez-Buylla A, Ling CY, Kirn JR (1990) Cresyl violet: a red fluorescent Nissl stain. J Neurosci Methods 33:129–133

CAS  PubMed  Google Scholar 

Benninger MS, Waters H (2009) Montelukast: pharmacology, safety, tolerability and efficacy. Clin Med. Ther 1:CMT.S1147

Google Scholar 

Bouvier DS, Murai KK (2015) Synergistic actions of microglia and astrocytes in the progression of alzheimer’s disease. J Alzheimers Dis 45:1001–1014

PubMed  Google Scholar 

Cai Y, Liu J, Wang B, Sun M, Yang H (2022) Microglia in the neuroinflammatory pathogenesis of Alzheimer’s disease and related therapeutic targets. Front Immunol 13:856376

CAS  PubMed  PubMed Central  Google Scholar 

Chen F, Ghosh A, Wu F, Tang S, Hu M, Sun H, Kong L, Hong H (2017) Preventive effect of genetic knockdown and pharmacological blockade of CysLT1R on lipopolysaccharide (LPS)-induced memory deficit and neurotoxicity in vivo. Brain Behav Immun 60:255–269

CAS  PubMed  Google Scholar 

Chen F, Ghosh A, Lin J, Zhang C, Pan Y, Thakur A, Singh K, Hong H, Tang S (2020) 5-lipoxygenase pathway and its downstream cysteinyl leukotrienes as potential therapeutic targets for Alzheimer’s disease. Brain Behav Immun 88:844–855

CAS  PubMed  Google Scholar 

Cummings J (2021) New approaches to symptomatic treatments for Alzheimer’s disease. Mol Neurodegener 16:2

PubMed  PubMed Central  Google Scholar 

Cummings J, Lee G, Nahed P, Kambar MEZN, Zhong K, Fonseca J, Taghva K (2022) Alzheimer’s disease drug development pipeline: 2022. 8:e12295

d’Isa R, Brambilla R, Fasano S (2014) Behavioral methods for the study of the Ras-ERK pathway in memory formation and consolidation: passive avoidance and novel object recognition tests. Methods Mol Biol (Clifton NJ) 1120:131–156

Datusalia AK, Singh G, Yadav N, Gaun S, Manik M, Singh RK (2022) Targeted delivery of Montelukast for the treatment of Alzheimer’s disease. CNS Neurol Disord Drug Targets 21:913–925

CAS  PubMed  Google Scholar 

de Oliveira BF, Veloso CA, Nogueira-Machado JA, de Moraes EN, dos Santos RR, Cintra MT, Chaves MM (2012) Ascorbic acid, alpha-tocopherol, and beta-carotene reduce oxidative stress and Proinflammatory cytokines in mononuclear cells of alzheimer’s disease patients. Nutr Neurosci 15:244–251

PubMed  Google Scholar 

Denninger JK, Smith BM, Kirby ED (2018) Novel object recognition and object location behavioral testing in mice on a budget. J Visualized Exp 141:e58593

Endres K, Reinhardt S, Geladaris A, Knies J, Grimm M, Hartmann T, Schmitt U (2016) Transnasal delivery of human A-beta peptides elicits impaired learning and memory performance in wild type mice. BMC Neurosci 17:44

PubMed  PubMed Central  Google Scholar 

Fang SC, Wang JJ, Chen F, Tang SS, Mu RH, Yuan DH, Zhao JJ, Hong H, Long Y (2021) Hippocampal CysLT1R overexpression or activation accelerates memory deficits, synaptic dysfunction, and amyloidogenesis in young APP/PS1 Transgenic mice. Ann Transl Med 9:1531

CAS  PubMed  PubMed Central  Google Scholar 

Gelosa P, Colazzo F, Tremoli E, Sironi L, Castiglioni L (2017) Cysteinyl leukotrienes as potential Pharmacological targets for cerebral diseases. Mediat Inflamm 2017:3454212

Google Scholar 

Ghosh A, Chen F, Thakur A, Hong H (2016) Cysteinyl leukotrienes and their receptors: emerging therapeutic targets in central nervous system disorders. CNS Neurosci Ther 22:943–951

CAS  PubMed  PubMed Central  Google Scholar 

Hadwan MH, Hussein MJ, Mohammed RM, Hadwan AM, Saad Al-Kawaz H, Al-Obaidy SSM, Al Talebi ZA (2024) An improved method for measuring catalase activity in biological samples. Biol Methods Protoc 9:bpae015

CAS  PubMed  PubMed Central  Google Scholar 

Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, Villemagne VL, Aisen P, Vendruscolo M, Iwatsubo T, Masters CL, Cho M, Lannfelt L, Cummings JL, Vergallo A (2021) The amyloid-β pathway in Alzheimer’s disease. Mol Psychiatry 26:5481–5503

CAS  PubMed  PubMed Central  Google Scholar 

Ishikura Y, Maeda-Minami A, Hosokawa M, Onoda A, Kawano Y, Ihara T, Sugamata M, Takeda K, Mano Y (2021) Leukotriene receptor antagonist use and dementia risk in patients with asthma: A retrospective cohort study. In Vivo (Athens Greece) 35:3297–3303

CAS  PubMed  Google Scholar 

Jeong SH, Jang JH, Lee YB (2023) Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factors. J Pharm Invest 53:119–152

Google Scholar 

Kalonia H, Kumar P, Kumar A, Nehru B (2010) Protective effect of Montelukast against quinolinic acid/malonic acid induced neurotoxicity: possible behavioral, biochemical, mitochondrial and tumor necrosis factor-α level alterations in rats. Neuroscience 171:284–299

CAS  PubMed  Google Scholar 

Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT (2018) Inflammation as a central mechanism in Alzheimer’s disease. Alzheimer’s & Dementia 4:575–590

Kiraly M, Foss JF, Giordano T (2023) Neuroinflammation, its role in Alzheimer’s disease and therapeutic strategies. J Prev Alzheimers Dis 10:686–698

CAS  PubMed  Google Scholar 

Kittana N, Hattab S, Ziyadeh-Isleem A, Jaradat N, Zaid A-N (2016) Montelukast, current indications and prospective future applications. Expert Rev Respir Med 10:943–956

CAS  PubMed  Google Scholar 

Laffleur F, Bauer B (2021) Progress in nasal drug delivery systems. Int J Pharm 607:120994

CAS  PubMed  Google Scholar 

Lai J, Hu M, Wang H, Hu M, Long Y, Miao MX, Li JC, Wang XB, Kong LY, Hong H (2014) Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates Aβ1-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice. Neuropharmacology 79:707–714

CAS  PubMed  Google Scholar 

Lasure VU, Singh Gautam A, Singh RK (2024) Quercetin ameliorates neuroinflammatory and neurodegenerative biomarkers in the brain and improves neurobehavioral parameters in a repeated intranasal amyloid-beta exposed model of Alzheimer’s disease. Food Funct 15:8712–8728

CAS  PubMed  Google Scholar 

Lecca D, Jung YJ, Scerba MT, Hwang I, Kim YK, Kim S, Modrow S, Tweedie D, Hsueh SC, Liu D, Luo W, Glotfelty E, Li Y, Wang JY, Luo Y, Hoffer BJ, Kim DS, McDevitt RA, Greig NH (2022) Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis. Alzheimers Dement J Alzheimers Assoc 18:2327–2340

CAS  Google Scholar 

Liu D, Lu J, Wei L, Yao M, Yang H, Lv P, Wang H, Zhu Y, Zhu Z, Zhang X, Chen J, Yang QX, Zhang B (2024) Olfactory deficit: a potential functional marker across the Alzheimer’s disease continuum. Front Neurosci 18:1309482

PubMed  PubMed Central  Google Scholar 

Luijerink L, Rodriguez M, Machaalani R (2024) Quantifying GFAP immunohistochemistry in the brain– introduction of the reactivity score (R-score) and how it compares to other methodologies. J Neurosci Methods 402:110025

CAS  PubMed  Google Scholar 

Marques CF, Marques MM, Justino GC (2022) Leukotrienes vs. Montelukast-activity, metabolism, and toxicity hints for repurposing. Pharmaceuticals 15:1039

CAS  PubMed  PubMed Central  Google Scholar 

Marschallinger J, Schäffner I, Klein B, Gelfert R, Rivera FJ, Illes S, Grassner L, Janssen M, Rotheneichner P, Schmuckermair C, Coras R, Boccazzi M, Chishty M, Lagler FB, Renic M, Bauer HC, Singewald N, Blümcke I, Bogdahn U, Couillard-Despres S, Lie DC, Abbracchio MP, Aigner L (2015) Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug. Nat Commun 6:8466

CAS  PubMed  Google Scholar 

Marschallinger J, Altendorfer B, Rockenstein E, Holztrattner M, Garnweidner-Raith J, Pillichshammer N, Leister I, Hutter-Paier B, Strempfl K, Unger MS, Chishty M, Felder T, Johnson M, Attems J, Masliah E, Aigner L (2020) The leukotriene receptor antagonist Montelukast reduces Alpha-Synuclein load and restores memory in an animal model of dementia with lewy bodies. Neurotherapeutics 17:1061–1074

CAS  PubMed  PubMed Central  Google Scholar 

Michael J, Marschallinger J, Aigner L (2019) The leukotriene signaling pathway: a druggable target in Alzheimer’s disease. Drug Discov Today 24:505–516

CAS  PubMed  Google Scholar 

Michael J, Bessa de Sousa D, Conway J, Gonzalez-Labrada E, Obeid R, Tevini J, Felder T, Hutter-Paier B, Zerbe H, Paiement N, Aigner L (2020) Improved bioavailability of Montelukast through a novel oral Mucoadhesive film in humans and mice. Pharmaceutics 13:12

Michael J, Zirknitzer J, Unger MS, Poupardin R, Rieß T, Paiement N, Zerbe H, Hutter-Paier B, Reitsamer H, Aigner L (2021) The leukotriene receptor antagonist Montelukast attenuates neuroinflammation and affects cognition in transgenic 5xFAD mice. Int J Mol Sci 22(5):2782. https://doi.org/10.3390/ijms22052782

CAS  PubMed  PubMed Central  Google Scholar 

Monaco A, Maffia V, Sorrentino NC, Sambri I, Ezhova Y, Giuliano T, Cacace V, Nusco E, De Risi M, De Leonibus E, Schrader T, Klärner FG, Bitan G, Fraldi A (2020) The amyloid inhibitor CLR01 relieves autophagy and ameliorates neuropathology in a severe lysosomal storage disease. Mol Ther: J Am Soc Gene Ther 28:1167–1176

CAS  Google Scholar 

Nagarajan VB, Marathe PA (2018) Effect of Montelukast in experimental model of Parkinson’s disease. Neurosci Lett 682:100–105

CAS  PubMed  Google Scholar 

Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358

CAS  PubMed  Google Scholar 

Pandya JD, Musyaju S,